Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Surg Pathol ; 48(7): 846-854, 2024 Jul 01.
Article in English | MEDLINE | ID: mdl-38809272

ABSTRACT

The detection of lymph node metastases is essential for breast cancer staging, although it is a tedious and time-consuming task where the sensitivity of pathologists is suboptimal. Artificial intelligence (AI) can help pathologists detect lymph node metastases, which could help alleviate workload issues. We studied how pathologists' performance varied when aided by AI. An AI algorithm was trained using more than 32 000 breast sentinel lymph node whole slide images (WSIs) matched with their corresponding pathology reports from more than 8000 patients. The algorithm highlighted areas suspicious of harboring metastasis. Three pathologists were asked to review a dataset comprising 167 breast sentinel lymph node WSIs, of which 69 harbored cancer metastases of different sizes, enriched for challenging cases. Ninety-eight slides were benign. The pathologists read the dataset twice, both digitally, with and without AI assistance, randomized for slide and reading orders to reduce bias, separated by a 3-week washout period. Their slide-level diagnosis was recorded, and they were timed during their reads. The average reading time per slide was 129 seconds during the unassisted phase versus 58 seconds during the AI-assisted phase, resulting in an overall efficiency gain of 55% ( P <0.001). These efficiency gains are applied to both benign and malignant WSIs. Two of the 3 reading pathologists experienced significant sensitivity improvements, from 74.5% to 93.5% ( P ≤0.006). This study highlights that AI can help pathologists shorten their reading times by more than half and also improve their metastasis detection rate.


Subject(s)
Artificial Intelligence , Breast Neoplasms , Lymphatic Metastasis , Sentinel Lymph Node Biopsy , Humans , Breast Neoplasms/pathology , Breast Neoplasms/diagnosis , Female , Lymphatic Metastasis/diagnosis , Lymphatic Metastasis/pathology , Image Interpretation, Computer-Assisted , Pathologists , Reproducibility of Results , Predictive Value of Tests , Observer Variation , Sentinel Lymph Node/pathology , Algorithms , Workflow
2.
Cytometry B Clin Cytom ; 92(4): 275-278, 2017 07.
Article in English | MEDLINE | ID: mdl-25916436

ABSTRACT

BACKGROUND: According to the 2008 World Health Organization (WHO) Classification of Tumors of the Haematopoietic and Lymphoid Tissues, the finding of B lymphoblasts in the blood or bone marrow of a patient with chronic myelogenous leukemia, BCR-ABL1+ (CML) should raise a concern for progression of the disease to B-lymphoblastic blast phase. Data addressing the incidence and phenotypic features of abnormal B lymphoblasts in CML, and whether the detection of B lymphoblasts inexorably heralds blast phase in CML, though, are limited. METHODS: We reviewed a consecutive series of patients with newly diagnosed CML who had undergone bone marrow examination with flow cytometric immunophenotyping. Polychromatic immunophenotyping data were reviewed, and clinical follow-up data were obtained. RESULTS: A precursor B-cell population with an abnormal composite immunophenotype was detected in 4 of 36 (11.1%) diagnostic bone marrow samples, at levels ranging from 0.01% to 0.30% of viable single cells acquired. The most common phenotypic aberrations were abnormally bright expression of CD10 and CD19 (seen in four and three cases, respectively), and abnormally dim expression of CD38 (seen in four cases). All three patients with adequate clinical follow-up have achieved and maintained a deep or major molecular response with a tyrosine kinase inhibitor, and none has progressed to B-lymphoblastic blast phase (follow-up duration: 17-46 months). CONCLUSIONS: In chronic-phase CML, a small (<0.5%) abnormal B-lymphoblast population is present in a significant minority of diagnostic bone marrow samples, but does not inevitably herald progression to B-lymphoblastic blast phase. © 2015 International Clinical Cytometry Society.


Subject(s)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Precursor Cells, B-Lymphoid/pathology , ADP-ribosyl Cyclase 1/blood , ADP-ribosyl Cyclase 1/genetics , Adult , Aged , Antigens, CD19/blood , Antigens, CD19/genetics , Antineoplastic Agents/therapeutic use , Biomarkers/blood , Female , Follow-Up Studies , Gene Expression , Humans , Immunophenotyping , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Male , Membrane Glycoproteins/blood , Membrane Glycoproteins/genetics , Middle Aged , Neprilysin/blood , Neprilysin/genetics , Precursor Cells, B-Lymphoid/immunology , Prognosis , Protein Kinase Inhibitors/therapeutic use , Treatment Outcome
3.
Arch Pathol Lab Med ; 137(11): 1684-7, 2013 Nov.
Article in English | MEDLINE | ID: mdl-24168511

ABSTRACT

Immunosuppressive drugs are an integral part of therapy in organ transplantation. However, they are not without side effects, and although rare, these agents should be considered in the differential diagnosis of pulmonary complications in patients receiving transplants. We present a case of a patient who developed acute respiratory failure 7 days after orthotopic heart transplantation and who had been on both mycophenolate mofetil (MMF) and tacrolimus agents. Lung biopsy revealed features of pulmonary hemorrhage with capillaritis. Considered as a possible etiology, MMF was withdrawn. There was immediate improvement of the patient's symptoms. The temporal relationship between MMF exposure and onset of pulmonary symptoms in the absence of other possible etiologies strongly suggests a causal relationship. Previously published reports of pulmonary toxicity from MMF included interstitial fibrosis. To the best of our knowledge, this is the first reported case of pulmonary hemorrhage with capillaritis because of administration of MMF.


Subject(s)
Heart Transplantation/adverse effects , Hemorrhage/chemically induced , Immunosuppressive Agents/adverse effects , Lung Diseases/chemically induced , Mycophenolic Acid/analogs & derivatives , Vasculitis/chemically induced , Hemorrhage/pathology , Humans , Immunosuppressive Agents/administration & dosage , Lung Diseases/pathology , Male , Middle Aged , Mycophenolic Acid/administration & dosage , Mycophenolic Acid/adverse effects , Tacrolimus/administration & dosage , Vasculitis/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...